GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (HKSE:02096) » Definitions » Forward PE Ratio

Simcere Pharmaceutical Group (HKSE:02096) Forward PE Ratio : 0.00 (As of Jun. 08, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Simcere Pharmaceutical Group Forward PE Ratio?

Simcere Pharmaceutical Group's Forward PE Ratio for today is 0.00.

Simcere Pharmaceutical Group's PE Ratio without NRI for today is 19.80.

Simcere Pharmaceutical Group's PE Ratio for today is 20.98.


Simcere Pharmaceutical Group Forward PE Ratio Historical Data

The historical data trend for Simcere Pharmaceutical Group's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group Forward PE Ratio Chart

Simcere Pharmaceutical Group Annual Data
Trend 2021-09 2022-12 2023-12
Forward PE Ratio
11.47 24.21 14.45

Simcere Pharmaceutical Group Semi-Annual Data
2021-03 2023-06
Forward PE Ratio 15.48 16.89

Competitive Comparison of Simcere Pharmaceutical Group's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Simcere Pharmaceutical Group's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Simcere Pharmaceutical Group's Forward PE Ratio falls into.



Simcere Pharmaceutical Group Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Simcere Pharmaceutical Group  (HKSE:02096) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Simcere Pharmaceutical Group Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Simcere Pharmaceutical Group (HKSE:02096) Business Description

Traded in Other Exchanges
Address
No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.
Executives
Wang Xi 2305 Beneficiary of a trust
Ren Jinsheng 2202 Interest of your spouse
Right Wealth Holdings Limited 2501 Other
Wang Xi 2501 Other
Simcere Investments Group Limited 2501 Other
Excel Investments Group Limited 2501 Other
Simcere Pharmaceutical Holding Limited 2501 Other
Simcere Holding Limited 2501 Other
Artking Global Limited 2501 Other
Ren Zhen 2501 Other
Ren Yong 2501 Other
Ren Weidong 2501 Other
Peng Suqin 2501 Other
P&h Holdings Group Ltd. 2501 Other
Li Shimeng 2501 Other

Simcere Pharmaceutical Group (HKSE:02096) Headlines

No Headlines